Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Dr. Noemi Puig Discusses Findings From the GEM2012MENOS65 Clinical Trial Presented at the 2021 ASH Meeting.
In this video, Dr. Noemi Puig outlines how next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of myeloma.
What is the topic of this video?
In patients (pts) with multiple myeloma (MM), next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of disease and to anticipate patient’s prognosis as compared to serum protein immunofixation (IFE). However, both methods rely on bone marrow (BM) samples and it is important to explore alternative techniques applicable in more accessible samples such as peripheral blood.
The use of IFE post-consolidation in pts with MM, as opposed to EXENT and NGF, did not identify pts with different PFS. When referred to NGF, EXENT provided a similar clinical value and displayed a very high NPV, increased further with the addition of LC-MS; this could be utilized to avoid the performance of a BM aspiration after treatment in pts with undetectable disease. Regarding EXENT+ and/or LC-MS+ cases future quantitative and sequential studies could reveal whether are due to the long half-lives of the MP or represent quiescent low-level disease.
ASH 2021: Abstract 544